Tuuli A. Nissinen

VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection

Markus Räsänen, Joni Degerman, Tuuli A. Nissinen et al. · Proceedings of the National Academy of Sciences · 2016 · 130 citations · Full text

Medicine, Oncology, Pharmacology +17

Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes

Tuuli A. Nissinen, Joni Degerman, Markus Räsänen et al. · Scientific Reports · 2016 · 64 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Prevention of chemotherapy‐induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle

Juha J. Hulmi, Tuuli A. Nissinen, Markus Räsänen et al. · Journal of Cachexia Sarcopenia and Muscle · 2017 · 60 citations · Full text

Medicine, Oncology, Pharmacology +14

Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses

Tuuli A. Nissinen, Jaakko Hentilä, Fabio Penna et al. · Journal of Cachexia Sarcopenia and Muscle · 2018 · 60 citations · Full text

Medicine, Oncology, Pharmacology +16

Muscle and serum metabolomes are dysregulated in colon-26 tumor-bearing mice despite amelioration of cachexia with activin receptor type 2B ligand blockade

Juulia Lautaoja-Kivipelto, Tuuli A. Nissinen, Jaakko Hentilä et al. · American Journal of Physiology-Endocrinology and Metabolism · 2019 · 34 citations · Full text

Medicine, Biochemistry, Oncology +17